Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery

Amiri-Kordestani L et al (2014) FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res 20:4436–4441. doi:10.1158/1078-0432.ccr-14-0012 PubMedCrossRef

Angeloni D, Danilkovitch-Miagkova A, Ivanov SV, Breathnach R, Johnson BE, Leonard EJ, Lerman MI (2000) Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. Genes Chromosomes Cancer 29:147–156PubMedCrossRef

Angeloni D, Danilkovitch-Miagkova A, Miagkov A, Leonard EJ, Lerman MI (2004) The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation. J Biol Chem 279:3726–3732. doi:10.1074/jbc.M309342200 PubMedCrossRef

Ardini E et al (2016) Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. Mol Cancer Ther 15:628–639. doi:10.1158/1535-7163.mct-15-0758 PubMedCrossRef

Bassett DI (2003) Identification and developmental expression of a macrophage stimulating 1/hepatocyte growth factor-like 1 orthologue in the zebrafish. Dev Genes Evol 213:360–362. doi:10.1007/s00427-003-0339-3 PubMedCrossRef

Batth IS, Yun H, Kumar AP (2015) Recepteur d’origine nantais (RON), more than a kinase: role in castrate-resistant prostate cancer. Mol Carcinog 54:937–946. doi:10.1002/mc.22354 PubMedCrossRef

Batth I et al (2016) Crosstalk between RON and androgen receptor signaling in the development of castration resistant prostate cancer. Oncotarget 7:14048–14063. doi:10.18632/oncotarget.7287 PubMedPubMedCentral

Benvenuti S, Lazzari L, Arnesano A, Li Chiavi G, Gentile A, Comoglio PM (2011) Ron kinase transphosphorylation sustains MET oncogene addiction. Cancer Res 71:1945–1955. doi:10.1158/0008-5472.can-10-2100 PubMedCrossRef

Biarc J, Chalkley RJ, Burlingame AL, Bradshaw RA (2011) Receptor tyrosine kinase signaling–a proteomic perspective. Adv Enzyme Regul 51:293–305. doi:10.1016/j.advenzreg.2010.10.005 PubMedCrossRef

Binetruy-Tournaire R et al (2000) Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 19:1525–1533. doi:10.1093/emboj/19.7.1525 PubMedPubMedCentralCrossRef

Blottiere HM, Steplewski Z, Herlyn D, Douillard JY (1991) Human anti-murine immunoglobulin responses and immune functions in cancer patients receiving murine monoclonal antibody therapy. Hum Antibodies Hybridomas 2:16–25PubMed

Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251:802–804PubMedCrossRef

Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J (2015) Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res 3:1148–1157. doi:10.1158/2326-6066.cir-15-0059 PubMedPubMedCentralCrossRef

Brand TM et al (2015) AXL is a logical molecular target in head and neck squamous cell carcinoma. Clin Cancer Res 21:2601–2612. doi:10.1158/1078-0432.ccr-14-2648 PubMedPubMedCentralCrossRef

Broussas M et al (2016) A new anti-CXCR4 antibody that blocks the CXCR4/SDF-1 axis and mobilizes effector cells. Mol Cancer Ther. doi:10.1158/1535-7163.mct-16-0041 PubMed

Brunelleschi S, Penengo L, Lavagno L, Santoro C, Colangelo D, Viano I, Gaudino G (2001) Macrophage stimulating protein (MSP) evokes superoxide anion production by human macrophages of different origin. Br J Pharmacol 134:1285–1295. doi:10.1038/sj.bjp.0704356 PubMedPubMedCentralCrossRef

Camp ER et al (2007) Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. Cancer 109:1030–1039. doi:10.1002/cncr.22490 PubMedCrossRef

Carafoli F, Chirgadze DY, Blundell TL, Gherardi E (2005) Crystal structure of the beta-chain of human hepatocyte growth factor-like/macrophage stimulating protein. FEBS J 272:5799–5807. doi:10.1111/j.1742-4658.2005.04968.x PubMedCrossRef

Carmi C, Mor M, Petronini PG, Alfieri RR (2012) Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem Pharmacol 84:1388–1399. doi:10.1016/j.bcp.2012.07.031 PubMedCrossRef

Catenacci DV et al (2011) RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther 12:9–46. doi:10.4161/cbt.12.1.15747 PubMedPubMedCentralCrossRef

Chakedis J et al (2016a) A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells. Oncogene 35:3249–3259. doi:10.1038/onc.2015.384 PubMedCrossRef

Chakedis J et al (2016b) Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics. Oncotarget. doi:10.18632/oncotarget.10009 PubMed

Chang K, Karnad A, Zhao S, Freeman JW (2015) Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets. Oncotarget 6:3507–3518. doi:10.18632/oncotarget.3420 PubMedPubMedCentralCrossRef

Chang HY et al (2016) RON nuclear translocation under hypoxia potentiates chemoresistance to DNA double-strand break-inducing anticancer drugs. Mol Cancer Ther 15:276–286. doi:10.1158/1535-7163.mct-15-0311 PubMedCrossRef

Chao KL, Tsai IW, Chen C, Herzberg O (2012) Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase. PLoS ONE 7:e41912. doi:10.1371/journal.pone.0041912 PubMedPubMedCentralCrossRef

Chao KL, Gorlatova NV, Eisenstein E, Herzberg O (2014) Structural basis for the binding specificity of human Recepteur d’Origine Nantais (RON) receptor tyrosine kinase to macrophage-stimulating protein. J Biol Chem 289:29948–29960. doi:10.1074/jbc.M114.594341 PubMedPubMedCentralCrossRef

Chen Q, Seol DW, Carr B, Zarnegar R (1997) Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology 26:59–66. doi:10.1002/hep.510260108 PubMed

Chen YQ, Zhou YQ, Angeloni D, Kurtz AL, Qiang XZ, Wang MH (2000) Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res 261:229–238. doi:10.1006/excr.2000.5012 PubMedCrossRef

Cheng HL et al (2005) Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer 92:1906–1914. doi:10.1038/sj.bjc.6602593 PubMedPubMedCentralCrossRef

Cho SB et al (2011) Small interfering RNA-directed targeting of RON alters invasive and oncogenic phenotypes of human hepatocellular carcinoma cells. Oncol Rep 26:1581–1586. doi:10.3892/or.2011.1435 PubMed

Choueiri TK et al (2013) Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 31:181–186. doi:10.1200/jco.2012.43.3383 PubMedCrossRef

Choura M, Rebai A (2011) Receptor tyrosine kinases: from biology to pathology. J Recept Sig Transduct Res 31:387–394. doi:10.3109/10799893.2011.625425 CrossRef

Chung CY et al (2012) Knockdown of RON inhibits AP-1 activity and induces apoptosis and cell cycle arrest through the modulation of Akt/FoxO signaling in human colorectal cancer cells. Dig Dis Sci 57:371–380. doi:10.1007/s10620-011-1892-7 PubMedCrossRef

Collesi C, Santoro MM, Gaudino G, Comoglio PM (1996) A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol 16:5518–5526PubMedPubMedCentralCrossRef

Correll PH, Iwama A, Tondat S, Mayrhofer G, Suda T, Bernstein A (1997) Deregulated inflammatory response in mice lacking the STK/RON receptor tyrosine kinase. Genes Funct 1:69–83PubMedCrossRef

Cote M, Miller AD, Liu SL (2007) Human RON receptor tyrosine kinase induces complete epithelial-to-mesenchymal transition but causes cellular senescence. Biochem Biophys Res Commun 360:219–225. doi:10.1016/j.bbrc.2007.06.033 PubMedPubMedCentralCrossRef

Cottage A, Clark M, Hawker K, Umrania Y, Wheller D, Bishop M, Elgar G (1999) Three receptor genes for plasminogen related growth factors in the genome of the puffer fish Fugu rubripes. FEBS Lett 443:370–374PubMedCrossRef

Cummings CT et al (2014) Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. Oncotarget 5:10434–10445. doi:10.18632/oncotarget.2142 PubMedPubMedCentralCrossRef

Danilkovitch A, Leonard EJ (1999) Kinases involved in MSP/RON signaling. J Leukoc Biol 65:345–348PubMed

Danilkovitch A, Miller M, Leonard EJ (1999a) Interaction of macrophage-stimulating protein with its receptor. Residues critical for beta chain binding and evidence for independent alpha chain binding. J Biol Chem 274:29937–29943PubMedCrossRef

Danilkovitch A, Skeel A, Leonard EJ (1999b) Macrophage stimulating protein-induced epithelial cell adhesion is mediated by a PI3-K-dependent, but FAK-independent mechanism. Exp Cell Res 248:575–582. doi:10.1006/excr.1999.4429 PubMedCrossRef

Danilkovitch-Miagkova A, Leonard EJ (2001) Cross-talk between RON receptor tyrosine kinase and other transmembrane receptors. Histol Histopathol 16:623–631PubMed

Danilkovitch-Miagkova A, Zbar B (2002) Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Investig 109:863–867. doi:10.1172/jci15418 PubMedPubMedCentralCrossRef

Danilkovitch-Miagkova A, Angeloni D, Skeel A, Donley S, Lerman M, Leonard EJ (2000) Integrin-mediated RON growth factor receptor phosphorylation requires tyrosine kinase activity of both the receptor and c-Src. J Biol Chem 275:14783–14786. doi:10.1074/jbc.C000028200 PubMedCrossRef

Danilkovitch-Miagkova A, Miagkov A, Skeel A, Nakaigawa N, Zbar B, Leonard EJ (2001) Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. Mol Cell Biol 21:5857–5868PubMedPubMedCentralCrossRef

Dassie JP, Giangrande PH (2013) Current progress on aptamer-targeted oligonucleotide therapeutics. Ther Deliv 4:1527–1546. doi:10.4155/tde.13.118 PubMedPubMedCentralCrossRef

Davis CG, Gallo ML, Corvalan JR (1999) Transgenic mice as a source of fully human antibodies for the treatment of cancer. Cancer Metastasis Rev 18:421–425PubMedCrossRef

de Goeij BE, Lambert JM (2016) New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol 40:14–23. doi:10.1016/j.coi.2016.02.008 PubMedCrossRef

De Maria R, Maggiora P, Biolatti B, Prat M, Comoglio PM, Castagnaro M, Di Renzo MF (2002) Feline STK gene expression in mammary carcinomas. Oncogene 21:1785–1790. doi:10.1038/sj.onc.1205221 PubMedCrossRef

Deantonio C, Cotella D, Macor P, Santoro C, Sblattero D (2014) Phage display technology for human monoclonal antibodies. Methods Mol Biol 1060:277–295. doi:10.1007/978-1-62703-586-6_14 PubMedCrossRef

Deng SJ, Liu W, Simmons CA, Moore JT, Tian G (2001) Identifying substrates for endothelium-specific Tie-2 receptor tyrosine kinase from phage-displayed peptide libraries for high throughput screening. Comb Chem High Throughput Screen 4:525–533PubMedCrossRef

Donate LE, Gherardi E, Srinivasan N, Sowdhamini R, Aparicio S, Blundell TL (1994) Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP). Protein Sci 3:2378–2394. doi:10.1002/pro.5560031222 PubMedPubMedCentralCrossRef

Eckerich C, Schulte A, Martens T, Zapf S, Westphal M, Lamszus K (2009) RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant. J Neurochem 109:969–980. doi:10.1111/j.1471-4159.2009.06027.x PubMedCrossRef

Faguet GB (2015) A brief history of cancer: age-old milestones underlying our current knowledge database. Int J Cancer 136:2022–2036. doi:10.1002/ijc.29134 PubMedCrossRef

Feng L, Yao HP, Wang W, Zhou YQ, Zhou J, Zhang R, Wang MH (2014) Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy. Clin Cancer Res 20:6045–6058. doi:10.1158/1078-0432.ccr-14-0898 PubMedCrossRef

Feng L, Wang W, Yao HP, Zhou J, Zhang R, Wang MH (2015) Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases. Methods Mol Biol 1233:151–159. doi:10.1007/978-1-4939-1789-1_14 PubMedCrossRef

Feng L, Yao HP, Zhou YQ, Zhou J, Zhang R, Wang MH (2016) Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. J Exp Clin Cancer Res 35:70. doi:10.1186/s13046-016-0347-6 PubMedPubMedCentralCrossRef

Feres KJ, Ischenko I, Hayman MJ (2009) The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells. Oncogene 28:279–288. doi:10.1038/onc.2008.383 PubMedCrossRef

Follenzi A, Bakovic S, Gual P, Stella MC, Longati P, Comoglio PM (2000) Cross-talk between the proto-oncogenes Met and Ron. Oncogene 19:3041–3049. doi:10.1038/sj.onc.1203620 PubMedCrossRef

Frenzel A, Schirrmann T, Hust M (2016) Phage display-derived human antibodies in clinical development and therapy. MAbs. doi:10.1080/19420862.2016.1212149 PubMedPubMedCentral

Ganesan R et al (2011) Proteolytic activation of pro-macrophage-stimulating protein by hepsin. Mol Cancer Res 9:1175–1186. doi:10.1158/1541-7786.mcr-11-0004 PubMedCrossRef

Gaudino G et al (1994) RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J 13:3524–3532PubMedPubMedCentral

Gaudino G, Avantaggiato V, Follenzi A, Acampora D, Simeone A, Comoglio PM (1995) The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues. Oncogene 11:2627–2637PubMed

Gaumann AK, Kiefer F, Alfer J, Lang SA, Geissler EK, Breier G (2016) Receptor tyrosine kinase inhibitors: Are they real tumor killers? Int J Cancer 138:540–554. doi:10.1002/ijc.29499 PubMedCrossRef

Gautschi O et al (2015) Targeted therapy for patients with BRAF-mutant lung cancer: results from the European EURAF Cohort. J Thorac Oncol 10:1451–1457. doi:10.1097/jto.0000000000000625 PubMedCrossRef

Geng L et al (2016) HER2 targeting peptides screening and applications in tumor imaging and drug delivery. Theranostics 6:1261–1273. doi:10.7150/thno.14302 PubMedPubMedCentralCrossRef

Gera N, Hussain M, Rao BM (2013) Protein selection using yeast surface display. Methods 60:15–26. doi:10.1016/j.ymeth.2012.03.014 PubMedCrossRef

Gherardi E, Gonzalez Manzano R, Cottage A, Hawker K, Aparicio S (1997) Evolution of plasminogen-related growth factors (HGF/SF and HGF1/MSP). Ciba Found Symp 212:24–35 (discussion 35–41, 42–25)PubMed

Golabek K, Strzelczyk JK, Wiczkowski A, Michalski M (2015) Potential use of histone deacetylase inhibitors in cancer therapy. Contemp Oncol (Pozn) 19:436–440. doi:10.5114/wo.2015.51824

Goyette P et al (2008) Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis. Mucosal Immunol 1:131–138. doi:10.1038/mi.2007.15 PubMedPubMedCentralCrossRef

Guin S, Yao HP, Wang MH (2010) RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity. Mol Pharm 7:386–397. doi:10.1021/mp900168v PubMedCrossRef

Guin S, Ma Q, Padhye S, Zhou YQ, Yao HP, Wang MH (2011) Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase. Cancer Chemother Pharmacol 67:1073–1083. doi:10.1007/s00280-010-1408-8 PubMedCrossRef

Gunes Z et al (2011) Isolation of fully human antagonistic RON antibodies showing efficient block of downstream signaling and cell migration. Transl Oncol 4:38–46PubMedPubMedCentralCrossRef

Gurusamy D, Gray JK, Pathrose P, Kulkarni RM, Finkleman FD, Waltz SE (2013) Myeloid-specific expression of Ron receptor kinase promotes prostate tumor growth. Cancer Res 73:1752–1763. doi:10.1158/0008-5472.can-12-2474 PubMedPubMedCentralCrossRef

Hamzeh-Mivehroud M, Mahmoudpour A, Dastmalchi S (2012) Identification of new peptide ligands for epidermal growth factor receptor using phage display and computationally modeling their mode of binding. Chem Biol Drug Des 79:246–259. doi:10.1111/j.1747-0285.2011.01282.x PubMedCrossRef

Hamzeh-Mivehroud M, Alizadeh AA, Morris MB, Church WB, Dastmalchi S (2013) Phage display as a technology delivering on the promise of peptide drug discovery. Drug Discovery Today 18:1144–1157. doi:10.1016/j.drudis.2013.09.001 PubMedCrossRef

Han S, Stuart LA, Degen SJ (1991) Characterization of the DNF15S2 locus on human chromosome 3: identification of a gene coding for four kringle domains with homology to hepatocyte growth factor. Biochemistry 30:9768–9780PubMedCrossRef

Han M et al (2010) 2LB Anti-tumor activity of anti-RON antibodies and biomarker of response. Eur J Cancer Suppl 8:3CrossRef

Han X et al (2013) Discovery and characterization of a novel cyclic peptide that effectively inhibits ephrin binding to the EphA4 receptor and displays anti-angiogenesis activity. PLoS ONE 8:e80183. doi:10.1371/journal.pone.0080183 PubMedPubMedCentralCrossRef

Hong CC et al (2008) Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 268:314–324. doi:10.1016/j.canlet.2008.04.017 PubMedCrossRef

Hubbard SR (1999) Structural analysis of receptor tyrosine kinases. Prog Biophys Mol Biol 71:343–358PubMedCrossRef

Hubbard SR, Miller WT (2007) Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol 19:117–123. doi:10.1016/j.ceb.2007.02.010 PubMedPubMedCentralCrossRef

Hui MK et al (2012) Prognostic significance of phosphorylated RON in esophageal squamous cell carcinoma. Med Oncol 29:1699–1706. doi:10.1007/s12032-011-0112-9 PubMedCrossRef

Hundhausen T, Laus R, Muller-Ruchholtz W (1992) New parental cell lines for generating human hybridomas. J Immunol Methods 153:21–29PubMedCrossRef

Inoue Y, Fujisawa M, Shoji M, Hashizume S, Katakura Y, Shirahata S (2000) Enhanced antibody production of human-human hybridomas by retinoic acid. Cytotechnology 33:83–88. doi:10.1023/a:1008155609072 PubMedPubMedCentralCrossRef

Iwama A, Okano K, Sudo T, Matsuda Y, Suda T (1994) Molecular cloning of a novel receptor tyrosine kinase gene, STK, derived from enriched hematopoietic stem cells. Blood 83:3160–3169PubMed

Iwama A, Yamaguchi N, Suda T (1996) STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family. EMBO J 15:5866–5875PubMedPubMedCentral

Jackson D et al (2008) A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res 68:9367–9374. doi:10.1158/0008-5472.can-08-1933 PubMedCrossRef

Jun HJ, Woolfenden S, Coven S, Lane K, Bronson R, Housman D, Charest A (2009) Epigenetic regulation of c-ROS receptor tyrosine kinase expression in malignant gliomas. Cancer Res 69:2180–2184. doi:10.1158/0008-5472.can-08-3351 PubMedCrossRef

Karasseva NG, Glinsky VV, Chen NX, Komatireddy R, Quinn TP (2002) Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. J Protein Chem 21:287–296PubMedCrossRef

Kariolis MS, Miao YR, Jones DS 2nd, Kapur S, Mathews II, Giaccia AJ, Cochran JR (2014) An engineered Axl ‘decoy receptor’ effectively silences the Gas6-Axl signaling axis. Nat Chem Biol 10:977–983. doi:10.1038/nchembio.1636 PubMedPubMedCentralCrossRef

Kawaguchi M, Orikawa H, Baba T, Fukushima T, Kataoka H (2009) Hepatocyte growth factor activator is a serum activator of single-chain precursor macrophage-stimulating protein. FEBS J 276:3481–3490. doi:10.1111/j.1742-4658.2009.07070.x PubMedCrossRef

Kim SA et al (2014) RON (recepteur d’origine nantais) expression and its association with tumor progression in laryngeal squamous cell carcinoma. Auris Nasus Larynx 41:201–206. doi:10.1016/j.anl.2013.10.014 PubMedCrossRef

Kim N et al (2016) Effect of Recepteur d’Origine Nantais expression on chemosensitivity and tumor cell behavior in colorectal cancer. Oncol Rep 35:3331–3340. doi:10.3892/or.2016.4721 PubMed

Ko JK, Auyeung KK (2014) Identification of functional peptides from natural and synthetic products on their anticancer activities by tumor targeting. Curr Med Chem 21:2346–2356PubMedCrossRef

Kobayashi T et al (2009) Transactivation of RON receptor tyrosine kinase by interaction with PDGF receptor beta during steady-state growth of human mesangial cells. Kidney Int 75:1173–1183. doi:10.1038/ki.2009.44 PubMedCrossRef

Koh YW, Hwang HS, Jung SJ, Park C, Yoon DH, Suh C, Huh J (2013) Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B-cell lymphoma patients receiving R-CHOP. Cancer Sci 104:1245–1251. doi:10.1111/cas.12215 PubMedCrossRef

Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497PubMedCrossRef

Krishnaswamy S, Mohammed AK, Amer OE, Tripathi G, Alokail MS, Al-Daghri NM (2015) Recepteur d’Origine nantais (RON) tyrosine kinase splicing variants lacking exons 18 and 19 occur ubiquitously in lung cancer. Int J Clin Exp Med 8:20778–20786PubMedPubMedCentral

Krishnaswamy S, Mohammed AK, Amer OE, Tripathi G, Alokail MS, Al-Daghri NM (2016) Novel splicing variants of recepteur d’origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer. Lung Cancer 92:41–46. doi:10.1016/j.lungcan.2015.12.002 PubMedCrossRef

Kudo T, Asao A, Tachibana T (1988) Highly efficient procedure for production of human monoclonal antibodies: establishment of hybrids between Epstein-Barr virus-transformed B lymphocytes and heteromyeloma cells by use of GIT culture medium. Tohoku J Exp Med 154:345–355PubMedCrossRef

Kudo T, Saeki H, Tachibana T (1991) A simple and improved method to generate human hybridomas. J Immunol Methods 145:119–125PubMedCrossRef

Kurihara N, Iwama A, Tatsumi J, Ikeda K, Suda T (1996) Macrophage-stimulating protein activates STK receptor tyrosine kinase on osteoclasts and facilitates bone resorption by osteoclast-like cells. Blood 87:3704–3710PubMed

Ladner RC, Sato AK, Gorzelany J, de Souza M (2004) Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today 9:525–529. doi:10.1016/s1359-6446(04)03104-6 PubMedCrossRef

Lamminmaki U, Nikolov D, Himanen J (2015) Eph receptors as drug targets: single-chain antibodies and beyond. Curr Drug Targets 16:1021–1030PubMedCrossRef

Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR (2005) Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res 11:2222–2228. doi:10.1158/1078-0432.ccr-04-1761 PubMedCrossRef

Lee CT, Chow NH, Su PF, Lin SC, Lin PC, Lee JC (2008) The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer. Dis Colon Rectum 51:1268–1274. doi:10.1007/s10350-008-9297-1 PubMedCrossRef

Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141:1117–1134. doi:10.1016/j.cell.2010.06.011 PubMedPubMedCentralCrossRef

Levitzki A (2013) Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu Rev Pharmacol Toxicol 53:161–185. doi:10.1146/annurev-pharmtox-011112-140341 PubMedCrossRef

Li BQ, Wang MH, Kung HF, Ronsin C, Breathnach R, Leonard EJ, Kamata T (1995) Macrophage-stimulating protein activates Ras by both activation and translocation of SOS nucleotide exchange factor. Biochem Biophys Res Commun 216:110–118. doi:10.1006/bbrc.1995.2598 PubMedCrossRef

Li Z, Yao H, Guin S, Padhye SS, Zhou YQ, Wang MH (2010) Monoclonal antibody (mAb)-induced down-regulation of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells. Int J Oncol 37:473–482PubMed

Li J, Chanda D, Shiri-Sverdlov R, Neumann D (2015) MSP: an emerging player in metabolic syndrome. Cytokine Growth Factor Rev 26:75–82. doi:10.1016/j.cytogfr.2014.10.007 PubMedCrossRef

Li H et al (2016) An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer. Cancer Biol Ther 17:346–354. doi:10.1080/15384047.2016.1139248 PubMedCrossRef

Lin CI et al (2014) TM4SF1: a new vascular therapeutic target in cancer. Angiogenesis 17:897–907. doi:10.1007/s10456-014-9437-2 PubMedPubMedCentralCrossRef

Lindzen M et al (2012) A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis. Oncogene 31:3505–3515. doi:10.1038/onc.2011.518 PubMedCrossRef

Lins L, Charloteaux B, Heinen C, Thomas A, Brasseur R (2006) “De novo” design of peptides with specific lipid-binding properties. Biophys J 90:470–479. doi:10.1529/biophysj.105.068213 PubMedCrossRef

Liu F et al (2015a) EGFR mutation promotes glioblastoma through epigenome and transcription factor network remodeling. Mol Cell 60:307–318. doi:10.1016/j.molcel.2015.09.002 PubMedPubMedCentralCrossRef

Liu F, Shen D, Kang X, Zhang C, Song Q (2015b) New tumour antigen PLAC1/CP1, a potentially useful prognostic marker and immunotherapy target for gastric adenocarcinoma. J Clin Pathol 68:913–916. doi:10.1136/jclinpath-2015-202978 PubMedCrossRef

Logan-Collins J et al (2010) Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res 70:1130–1140. doi:10.1158/0008-5472.can-09-0761 PubMedPubMedCentralCrossRef

Loizos N, Bailey T, Topper M, Eastman S, Pennello A, O’Toole J (2011) Abstract C54: in vitro and in vivo anti-tumor activity of the antimacrophage stimulating 1-receptor antibody IMC-RON8 in breast and bladder cancer models. Mol Cancer Ther 10:C54CrossRef

Lonberg N (2008) Human monoclonal antibodies from transgenic mice. In: Handbook of experimental pharmacology, pp 69–97 doi:10.1007/978-3-540-73259-4_4

Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, Chari R, Jordan MA (2010) Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 9:2689–2699. doi:10.1158/1535-7163.mct-10-0644 PubMedPubMedCentralCrossRef

Lu Y, Yao HP, Wang MH (2007) Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett 257:157–164. doi:10.1016/j.canlet.2007.08.007 PubMedCrossRef

Lu Y, Yao HP, Wang MH (2008) Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160. J Exp Clin Cancer Res 27:55. doi:10.1186/1756-9966-27-55 PubMedPubMedCentralCrossRef

Ma Q, Zhang K, Guin S, Zhou YQ, Wang MH (2010a) Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase. Mol Cancer 9:307. doi:10.1186/1476-4598-9-307 PubMedPubMedCentralCrossRef

Ma Q, Zhang K, Yao HP, Zhou YQ, Padhye S, Wang MH (2010b) Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence. Int J Oncol 36:1551–1561PubMed

Ma Q, Guin S, Padhye SS, Zhou YQ, Zhang RW, Wang MH (2011) Ribosomal protein S6 kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein. Mol Cancer 10:66. doi:10.1186/1476-4598-10-66 PubMedPubMedCentralCrossRef

Ma Y, Liu J, Shi H, Yu LL (2016) Isolation and characterization of anti-inflammatory peptides derived from whey protein. J Dairy Sci. doi:10.3168/jds.2016-11186

Maggiora P et al (1998) Overexpression of the RON gene in human breast carcinoma. Oncogene 16:2927–2933. doi:10.1038/sj.onc.1201812 PubMedCrossRef

Maggiora P et al (2003) The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res 288:382–389PubMedCrossRef

Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912–1934. doi:10.1126/science.1075762 PubMedCrossRef

Matzke A, Herrlich P, Ponta H, Orian-Rousseau V (2005) A five-amino-acid peptide blocks Met- and Ron-dependent cell migration. Cancer Res 65:6105–6110. doi:10.1158/0008-5472.can-05-0207 PubMedCrossRef

McClaine RJ, Marshall AM, Wagh PK, Waltz SE (2010) Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines. Neoplasia 12:650–658PubMedPubMedCentralCrossRef

McCoach CE, Bivona TG, Blakely CM, Doebele RC (2016) Neoadjuvant oncogene-targeted therapy in early stage non-small-cell lung cancer as a strategy to improve clinical outcome and identify early mechanisms of resistance. Clin Lung Cancer. doi:10.1016/j.cllc.2016.05.025 PubMed

McDowell SA et al (2002) The role of the receptor tyrosine kinase Ron in nickel-induced acute lung injury. Am J Respir Cell Mol Biol 26:99–104. doi:10.1165/ajrcmb.26.1.4621 PubMedCrossRef

McGuire S (2016) World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 7:418–419. doi:10.3945/an.116.012211 PubMedCrossRef

Medico E et al (1996) The tyrosine kinase receptors Ron and Sea control “scattering” and morphogenesis of liver progenitor cells in vitro. Mol Biol Cell 7:495–504PubMedPubMedCentralCrossRef

Mereiter S et al (2016) Glycomic analysis of gastric carcinoma cells discloses glycans as modulators of RON receptor tyrosine kinase activation in cancer. Biochim Biophys Acta 1860:1795–1808. doi:10.1016/j.bbagen.2015.12.016 PubMedCrossRef

Mompo SM, Gonzalez-Fernandez A (2014) Antigen-specific human monoclonal antibodies from transgenic mice. Methods Mol Biol 1060:245–276. doi:10.1007/978-1-62703-586-6_13 PubMedCrossRef

Monge J, Kricun M, Radovcic J, Radovcic D, Mann A, Frayer DW (2013) Fibrous dysplasia in a 120,000+ year old Neandertal from Krapina, Croatia. PloS One 8:e64539. doi:10.1371/journal.pone.0064539 PubMedPubMedCentralCrossRef

Montero-Julian FA et al (1998) Characterization of two monoclonal antibodies against the RON tyrosine kinase receptor. Hybridoma 17:541–551. doi:10.1089/hyb.1998.17.541 PubMedCrossRef

Mu Q, Kievit FM, Kant RJ, Lin G, Jeon M, Zhang M (2015) Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells. Nanoscale 7:18010–18014. doi:10.1039/c5nr04867b PubMedCrossRef

Mullard A (2015) 2014 FDA drug approvals. Nat Rev Drug Discovery 14:77–81. doi:10.1038/nrd4545 PubMedCrossRef

Mullard A (2016) 2015 FDA drug approvals. Nat Rev Drug Discovery 15:73–76. doi:10.1038/nrd.2016.15 PubMedCrossRef

Nakamura T, Aoki S, Takahashi T, Matsumoto K, Kiyohara T, Nakamura T (1996) Cloning and expression of Xenopus HGF-like protein (HLP) and Ron/HLP receptor implicate their involvement in early neural development. Biochem Biophys Res Commun 224:564–573. doi:10.1006/bbrc.1996.1065 PubMedCrossRef

Northrup AB et al (2013) Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): a specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met. J Med Chem 56:2294–2310. doi:10.1021/jm301619u PubMedCrossRef

Odegrip R et al (2004) CIS display: in vitro selection of peptides from libraries of protein-DNA complexes. Proc Natl Acad Sci USA 101:2806–2810. doi:10.1073/pnas.0400219101 PubMedPubMedCentralCrossRef

Ohshiro K et al (1996) Molecular cloning of rat macrophage-stimulating protein and its involvement in the male reproductive system. Biochem Biophys Res Commun 227:273–280. doi:10.1006/bbrc.1996.1500 PubMedCrossRef

Olsson L, Kaplan HS (1980) Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. Proc Natl Acad Sci USA 77:5429–5431PubMedPubMedCentralCrossRef

O’Toole JM et al (2006) Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 66:9162–9170. doi:10.1158/0008-5472.can-06-0283 PubMedCrossRef

Padhye SS, Guin S, Yao HP, Zhou YQ, Zhang R, Wang MH (2011) Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics. Mol Pharm 8:2310–2319. doi:10.1021/mp200193u PubMedCrossRef

Pan D (2015) YAPing hippo forecasts a new target for lung cancer prevention and treatment. J Clin Oncol 33:2311–2313. doi:10.1200/jco.2015.61.2093 PubMedPubMedCentralCrossRef

Park JS, Park JH, Lee S, Joo YE, Jung YD (2010) Small interfering RNA targeting of Recepteur d’Origine Nantais induces apoptosis via modulation of nuclear factor-kappaB and Bcl-2 family in gastric cancer cells. Oncol Rep 24:709–714PubMed

Park JS, Park JH, Khoi PN, Joo YE, Jung YD (2011) MSP-induced RON activation upregulates uPAR expression and cell invasiveness via MAPK, AP-1 and NF-kappaB signals in gastric cancer cells. Carcinogenesis 32:175–181. doi:10.1093/carcin/bgq241 PubMedCrossRef

Park YL et al (2012) Expression of RON in colorectal cancer and its relationships with tumor cell behavior and prognosis. Tumori 98:652–662. doi:10.1700/1190.13208 PubMed

Patton KT et al (2004) Expression of RON Proto-oncogene in renal oncocytoma and chromophobe renal cell carcinoma. Am J Surg Pathol 28:1045–1050PubMedCrossRef

Peace BE, Hughes MJ, Degen SJ, Waltz SE (2001) Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis. Oncogene 20:6142–6151. doi:10.1038/sj.onc.1204836 PubMedCrossRef

Peace BE, Hill KJ, Degen SJ, Waltz SE (2003) Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor. Exp Cell Res 289:317–325PubMedCrossRef

Phillips AC et al (2016) ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Mol Cancer Ther 15:661–669. doi:10.1158/1535-7163.mct-15-0901 PubMedCrossRef

Pillay V et al (2009) The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 11:448–458PubMedPubMedCentralCrossRef

Pinilla C, Appel JR, Blanc P, Houghten RA (1992) Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries. Biotechniques 13:901–905PubMed

Pirogova E, Istivan T, Gan E, Cosic I (2011) Advances in methods for therapeutic peptide discovery, design and development. Curr Pharm Biotechnol 12:1117–1127PubMedCrossRef

Polakis P (2016) Antibody drug conjugates for CANCER therapy. Pharmacol Rev 68:3–19. doi:10.1124/pr.114.009373 PubMedCrossRef

Ponzetto C et al (1994) A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77:261–271PubMedCrossRef

Prislei S et al (2010) RON and cisplatin resistance in ovarian cancer cell lines. Oncol Res 19:13–22PubMedCrossRef

Quantin B, Schuhbaur B, Gesnel MC, Doll’e P, Breathnach R (1995) Restricted expression of the ron gene encoding the macrophage stimulating protein receptor during mouse development. Dev Dyn 204:383–390. doi:10.1002/aja.1002040405 PubMedCrossRef

Raeppel S et al (2010) Identification of a novel series of potent RON receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 20:2745–2749. doi:10.1016/j.bmcl.2010.03.073 PubMedCrossRef

Raeppel F, Raeppel SL, Therrien E (2015a) Design, synthesis and RON receptor tyrosine kinase inhibitory activity of new head groups analogs of LCRF-0004. Bioorg Med Chem Lett 25:3810–3815. doi:10.1016/j.bmcl.2015.07.080 PubMedCrossRef

Raeppel SL, Raeppel F, Therrien E (2015b) Design and synthesis of close analogs of LCRF-0004, a potent and selective RON receptor tyrosine kinase inhibitor. Bioorg Med Chem Lett 25:2527–2531. doi:10.1016/j.bmcl.2015.04.056 PubMedCrossRef

Raeppel SL, Therrien E, Raeppel F (2015c) Design and synthesis of constrained analogs of LCRF-0004 as potent RON tyrosine kinase inhibitors. Bioorg Med Chem Lett 25:3706–3710. doi:10.1016/j.bmcl.2015.06.034 PubMedCrossRef

Rampino T, Collesi C, Gregorini M, Maggio M, Soccio G, Guallini P, Dal Canton A (2002) Macrophage-stimulating protein is produced by tubular cells and activates mesangial cells. J Am Soc Nephrol 13:649–657PubMed

Rampino T et al (2007) Neutralization of macrophage-stimulating protein ameliorates renal injury in anti-thy 1 glomerulonephritis. J Am Soc Nephrol 18:1486–1496. doi:10.1681/asn.2006060680 PubMedCrossRef

Reardon DA et al (2012) Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol 69:1507–1518. doi:10.1007/s00280-012-1854-6 PubMedPubMedCentralCrossRef

Riechmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332:323–327. doi:10.1038/332323a0 PubMedCrossRef

Riedl SJ, Pasquale EB (2015) Targeting the Eph system with peptides and peptide conjugates. Curr Drug Targets 16:1031–1047PubMedPubMedCentralCrossRef

Ronca R, Benzoni P, De Luca A, Crescini E, Dell’era P (2012) Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics. Int J Mol Sci 13:5254–5277. doi:10.3390/ijms13045254 PubMedPubMedCentralCrossRef

Ronsin C, Muscatelli F, Mattei MG, Breathnach R (1993) A novel putative receptor protein tyrosine kinase of the met family. Oncogene 8:1195–1202PubMed

Saber H, Leighton JK (2015) An FDA oncology analysis of antibody-drug conjugates. Regul Toxicol Pharmacol 71:444–452. doi:10.1016/j.yrtph.2015.01.014 PubMedCrossRef

Sakahara H et al (1997) Anti-murine antibody response to mouse monoclonal antibodies in cancer patients. Jpn J Cancer Res 88:895–899PubMedCrossRef

Sakamoto O et al (1997) Role of macrophage-stimulating protein and its receptor, RON tyrosine kinase, in ciliary motility. J Clin Investig 99:701–709. doi:10.1172/jci119214 PubMedPubMedCentralCrossRef

Sakorafas GH, Safioleas M (2009) Breast cancer surgery: an historical narrative. Part I. From prehistoric times to renaissance. Eur J Cancer Care (English Language Edition) 18:530–544. doi:10.1111/j.1365-2354.2008.01059.x CrossRef

Santoro MM, Penengo L, Minetto M, Orecchia S, Cilli M, Gaudino G (1998) Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor. Oncogene 17:741–749. doi:10.1038/sj.onc.1201994 PubMedCrossRef

Santoro MM, Gaudino G, Marchisio PC (2003) The MSP receptor regulates alpha6beta4 and alpha3beta1 integrins via 14-3-3 proteins in keratinocyte migration. Dev Cell 5:257–271PubMedCrossRef

Scheid C et al (2015) Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. Eur J Haematol 95:316–324. doi:10.1111/ejh.12491 PubMedCrossRef

Schiff D et al (2015) Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. Invest New Drugs 33:247–253. doi:10.1007/s10637-014-0186-2 PubMedCrossRef

Serrels A, Frame MC (2016) FAK goes nuclear to control antitumor immunity-a new target in cancer immuno-therapy. Oncoimmunology 5:e1119356. doi:10.1080/2162402x.2015.1119356 PubMedCrossRef

Shimamoto A, Kimura T, Matsumoto K, Nakamura T (1993) Hepatocyte growth factor-like protein is identical to macrophage stimulating protein. FEBS Lett 333:61–66PubMedCrossRef

Skeel A, Yoshimura T, Showalter SD, Tanaka S, Appella E, Leonard EJ (1991) Macrophage stimulating protein: purification, partial amino acid sequence, and cellular activity. J Exp Med 173:1227–1234PubMedCrossRef

Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315–1317PubMedCrossRef

Song YA et al (2012) RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer. Pathol Int 62:127–136. doi:10.1111/j.1440-1827.2011.02765.x PubMedCrossRef

Spanheimer PM et al (2015) Receptor tyrosine kinase expression predicts response to sunitinib in breast cancer. Ann Surg Oncol 22:4287–4294. doi:10.1245/s10434-015-4597-x PubMedPubMedCentralCrossRef

Steinig AG et al (2013) Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases. Bioorg Med Chem Lett 23:4381–4387. doi:10.1016/j.bmcl.2013.05.074 PubMedCrossRef

Stephenson SA, Douglas EL, Mertens-Walker I, Lisle JE, Maharaj MS, Herington AC (2015) Anti-tumour effects of antibodies targeting the extracellular cysteine-rich region of the receptor tyrosine kinase EphB4. Oncotarget 6:7554–7569. doi:10.18632/oncotarget.3199 PubMedPubMedCentralCrossRef

Stuart WD, Kulkarni RM, Gray JK, Vasiliauskas J, Leonis MA, Waltz SE (2011) Ron receptor regulates Kupffer cell-dependent cytokine production and hepatocyte survival following endotoxin exposure in mice. Hepatology 53:1618–1628. doi:10.1002/hep.24239 PubMedPubMedCentralCrossRef

Sudhakar A (2009) History of Cancer, Ancient and Modern Treatment Methods. Journal of Cancer Science & Therapy 1:1–4. doi:10.4172/1948-5956.100000e2 CrossRef

Tactacan CM et al (2012) RON is not a prognostic marker for resectable pancreatic cancer. BMC Cancer 12:395. doi:10.1186/1471-2407-12-395 PubMedPubMedCentralCrossRef

Tauro M, McGuire J, Lynch CC (2014) New approaches to selectively target cancer-associated matrix metalloproteinase activity. Cancer Metastasis Rev 33:1043–1057. doi:10.1007/s10555-014-9530-4 PubMedCrossRef

Thapa RK et al (2016) Liquid crystalline nanoparticles encapsulating cisplatin and docetaxel combination for targeted therapy of breast cancer. Biomater Sci. doi:10.1039/c6bm00376a PubMed

Thery C, Sharpe MJ, Batley SJ, Stern CD, Gherardi E (1995) Expression of HGF/SF, HGF1/MSP, and c-met suggests new functions during early chick development. Dev Genet 17:90–101. doi:10.1002/dvg.1020170110 PubMedCrossRef

Thomas RM et al (2007) The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 67:6075–6082. doi:10.1158/0008-5472.can-06-4128 PubMedCrossRef

Tolmachev V, Orlova A, Nilsson FY, Feldwisch J, Wennborg A, Abrahmsen L (2007) Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther 7:555–568. doi:10.1517/14712598.7.4.555 PubMedCrossRef

Tomita M, Tsumoto K (2011) Hybridoma technologies for antibody production. Immunotherapy 3:371–380. doi:10.2217/imt.11.4 PubMedCrossRef

Wang Z, Zhang X (2016) Isolation and identification of anti-proliferative peptides from Spirulina platensis using three-step hydrolysis. J Sci Food Agric. doi:10.1002/jsfa.7815 PubMedCentral

Wang MH, Gonias SL, Skeel A, Wolf BB, Yoshimura T, Leonard EJ (1994a) Proteolytic activation of single-chain precursor macrophage-stimulating protein by nerve growth factor-gamma and epidermal growth factor-binding protein, members of the kallikrein family. J Biol Chem 269:13806–13810PubMed

Wang MH, Ronsin C, Gesnel MC, Coupey L, Skeel A, Leonard EJ, Breathnach R (1994b) Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science 266:117–119PubMedCrossRef

Wang MH, Yoshimura T, Skeel A, Leonard EJ (1994c) Proteolytic conversion of single chain precursor macrophage-stimulating protein to a biologically active heterodimer by contact enzymes of the coagulation cascade. J Biol Chem 269:3436–3440PubMed

Wang MH, Dlugosz AA, Sun Y, Suda T, Skeel A, Leonard EJ (1996a) Macrophage-stimulating protein induces proliferation and migration of murine keratinocytes. Exp Cell Res 226:39–46. doi:10.1006/excr.1996.0200 PubMedCrossRef

Wang MH, Montero-Julian FA, Dauny I, Leonard EJ (1996b) Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein. Oncogene 13:2167–2175PubMed

Wang MH, Kurtz AL, Chen Y (2000) Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis 21:1507–1512PubMedCrossRef

Wang MH, Lee W, Luo YL, Weis MT, Yao HP (2007) Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol 213:402–411. doi:10.1002/path.2245 PubMedCrossRef

Wang J, Steinbacher S, Augustin M, Schreiner P, Epstein D, Mulvihill MJ, Crew AP (2010) The crystal structure of a constitutively active mutant RON kinase suggests an intramolecular autophosphorylation hypothesis. Biochemistry 49:7972–7974. doi:10.1021/bi100409w PubMedCrossRef

Wang D, Lao WF, Kuang YY, Geng SM, Mo LJ, He C (2012) A novel variant of the RON receptor tyrosine kinase derived from colorectal carcinoma cells which lacks tyrosine phosphorylation but induces cell migration. Exp Cell Res 318:2548–2558. doi:10.1016/j.yexcr.2012.08.006 PubMedCrossRef

Wang MH, Zhang R, Zhou YQ, Yao HP (2013a) Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction. J Biomed Res 27:345–356. doi:10.7555/jbr.27.20130038 PubMedPubMedCentralCrossRef

Wang Q, Quan H, Zhao J, Xie C, Wang L, Lou L (2013b) RON confers lapatinib resistance in HER2-positive breast cancer cells. Cancer Lett 340:43–50. doi:10.1016/j.canlet.2013.06.022 PubMedCrossRef

Watanabe H et al (2015) Prognostic value of hepatocyte growth factor receptor expression in patients with perihilar cholangiocarcinoma. Ann Surg Oncol 22:2235–2242. doi:10.1245/s10434-014-4170-z PubMedCrossRef

Weinstein IB (2002) Cancer. addiction to oncogenes–the Achilles heal of cancer. Science 297:63–64. doi:10.1126/science.1073096 PubMedCrossRef

Wesolowski R, Markowitz J, Carson WE 3rd (2013) Myeloid derived suppressor cells—a new therapeutic target in the treatment of cancer. J Immunother Cancer 1:10. doi:10.1186/2051-1426-1-10 PubMedPubMedCentralCrossRef

Westerlund-Wikstrom B (2000) Peptide display on bacterial flagella: principles and applications. Int J Med Microbiol 290:223–230. doi:10.1016/s1438-4221(00)80119-8 PubMedCrossRef

Whalen K et al (2011) Anti-tumor activities of antibodies targeting the RON receptor and a biomarker of response. Cancer Res 71:644CrossRef

Willett CG et al (1997) Differential screening of a human chromosome 3 library identifies hepatocyte growth factor-like/macrophage-stimulating protein and its receptor in injured lung. Possible implications for neuroendocrine cell survival. J Clin Investig 99:2979–2991. doi:10.1172/jci119493 PubMedPubMedCentralCrossRef

Williams R (2015) Discontinued in 2013: oncology drugs. Expert Opin Investig Drugs 24:95–110PubMedCrossRef

Williams TA, Longati P, Pugliese L, Gual P, Bardelli A, Michieli P (1999) MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential. J Cell Physiol 181:507–514. doi:10.1002/(sici)1097-4652(199912)181:3<507:aid-jcp15>3.0.co;2-q PubMedCrossRef

Wilson DS, Keefe AD, Szostak JW (2001) The use of mRNA display to select high-affinity protein-binding peptides. Proc Natl Acad Sci USA 98:3750–3755. doi:10.1073/pnas.061028198 PubMedPubMedCentralCrossRef

Wilson CB, Ray M, Lutz M, Sharda D, Xu J, Hankey PA (2008) The RON receptor tyrosine kinase regulates IFN-gamma production and responses in innate immunity. J Immunol 181:2303–2310PubMedCrossRef

Wu Z et al (2015) Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer. Oncotarget 6:40519–40534. doi:10.18632/oncotarget.5816 PubMedPubMedCentral

Wu P, Nielsen TE, Clausen MH (2016) Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Drug Discov Today 21:5–10. doi:10.1016/j.drudis.2015.07.008 PubMedCrossRef

Xiangming X, Yun Q, Guoliang Z, Jianjiang L, Lisong T (2011) Mechanisms of RON-mediated epithelial-mesenchymal transition in MDCK cells through the MAPK pathway. Braz J Med Biol Res 44:634–641PubMed

Xiao Y, Freeman GJ (2015) A New B7:CD28 family checkpoint target for cancer immunotherapy: HHLA2. Clin Cancer Res 21:2201–2203. doi:10.1158/1078-0432.ccr-14-2658 PubMedPubMedCentralCrossRef

Xiao ZQ, Chen YQ, Wang MH (2000) Requirement of both tyrosine residues 1330 and 1337 in the C-terminal tail of the RON receptor tyrosine kinase for epithelial cell scattering and migration. Biochem Biophys Res Commun 267:669–675. doi:10.1006/bbrc.1999.2011 PubMedCrossRef

Xu AM, Huang PH (2010) Receptor tyrosine kinase coactivation networks in cancer. Cancer Res 70:3857–3860. doi:10.1158/0008-5472.can-10-0163 PubMedPubMedCentralCrossRef

Xu XM, Wang D, Shen Q, Chen YQ, Wang MH (2004) RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene 23:8464–8474. doi:10.1038/sj.onc.1207907 PubMedCrossRef

Xu W, Yang Z, Lu N (2016) Molecular targeted therapy for the treatment of gastric cancer. J Exp Clin Cancer Res 35:1. doi:10.1186/s13046-015-0276-9 PubMedPubMedCentralCrossRef

Yang F, Ai W, Jiang F, Liu X, Huang Z, Ai S (2016) Preclinical evaluation of an epidermal growth factor receptor-targeted doxorubicin-peptide conjugate: toxicity, biodistribution, and efficacy in mice. J Pharm Sci 105:639–649. doi:10.1016/j.xphs.2015.10.020 PubMedCrossRef

Yao HP, Luo YL, Feng L, Cheng LF, Lu Y, Li W, Wang MH (2006) Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Cancer Biol Ther 5:1179–1186PubMedCrossRef

Yao HP, Zhou YQ, Ma Q, Guin S, Padhye SS, Zhang RW, Wang MH (2011) The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells. Mol Cancer 10:82. doi:10.1186/1476-4598-10-82 PubMedPubMedCentralCrossRef

Yao HP, Zhou YQ, Zhang R, Wang MH (2013) MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer 13:466–481. doi:10.1038/nrc3545 PubMedCrossRef

Yao HP, Feng L, Zhou JW, Zhang RW, Wang MH (2016) Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment. Am J Cancer Res 6:937–956PubMedPubMedCentral

Yokoyama N, Ischenko I, Hayman MJ, Miller WT (2005) The C terminus of RON tyrosine kinase plays an autoinhibitory role. J Biol Chem 280:8893–8900. doi:10.1074/jbc.M412623200 PubMedCrossRef

Yoon TM et al (2013) Expression of the receptor tyrosine kinase recepteur d’origine nantais and its association with tumor progression in hypopharyngeal cancer. Head Neck 35:1106–1113. doi:10.1002/hed.23090 PubMedCrossRef

Yoshimura T, Yuhki N, Wang MH, Skeel A, Leonard EJ (1993) Cloning, sequencing, and expression of human macrophage stimulating protein (MSP, MST1) confirms MSP as a member of the family of kringle proteins and locates the MSP gene on chromosome 3. J Biol Chem 268:15461–15468PubMed

Yu PT et al (2012) The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome. Int J Cancer 131:1744–1754. doi:10.1002/ijc.27447 PubMedPubMedCentralCrossRef

Yu H, Yuan J, Xiao C, Qin Y (2013) Integrative genomic analyses of recepteur d’origine nantais and its prognostic value in cancer. Int J Mol Med 31:1248–1254. doi:10.3892/ijmm.2013.1296 PubMed

Yu MZ et al (2016) Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer. Eur J Pharm Sci 92:39–48. doi:10.1016/j.ejps.2016.06.020 PubMedCrossRef

Zhang Y et al (2008) Identification of a novel recepteur d’origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res 68:6680–6687. doi:10.1158/0008-5472.can-07-6782 PubMedCrossRef

Zhang K, Zhou YQ, Yao HP, Wang MH (2010) Alterations in a defined extracellular region of the RON receptor tyrosine kinase promote RON-mediated motile and invasive phenotypes in epithelial cells. Int J Oncol 36:255–264PubMed

Zhang N, Chang Y, Rios A, An Z (2016) HER3/ErbB3, an emerging cancer therapeutic target. Acta Biochim Biophys Sin (Shanghai) 48:39–48. doi:10.1093/abbs/gmv103

Zhao P et al (2007) Identification of a met-binding peptide from a phage display library. Clin Cancer Res 13:6049–6055. doi:10.1158/1078-0432.ccr-07-0035 PubMedCrossRef

Zhao H et al (2014) The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer. Oncogene 33:1429–1437. doi:10.1038/onc.2013.84 PubMedCrossRef

Zhou YQ, He C, Chen YQ, Wang D, Wang MH (2003) Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene 22:186–197. doi:10.1038/sj.onc.1206075 PubMedCrossRef

Zhou D, Pan G, Zheng C, Zheng J, Yian L, Teng X (2008) Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues. BMC Cancer 8:353. doi:10.1186/1471-2407-8-353 PubMedPubMedCentralCrossRef

Zhou P, Wang C, Ren Y, Yang C, Tian F (2013) Computational peptidology: a new and promising approach to therapeutic peptide design. Curr Med Chem 20:1985–1996PubMedCrossRef

Zhou DH, Li C, Yang LN (2015) Variant RONDelta160 of the RON receptor tyrosine kinase promotes the growth and invasion in vitro and in vivo in gastric cancer cell lines. Cancer Cell Int 15:9. doi:10.1186/s12935-015-0157-5 PubMedPubMedCentralCrossRef

Zhuang XP, Jin WW, Teng XD, Yuan ZZ, Lin QQ, Xu ST (2015) c-Met and RON expression levels in endometrial adenocarcinoma tissue and their relationship with prognosis. Eur J Gynaecol Oncol 36:255–259PubMed

Zinser GM et al (2006) Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res 66:11967–11974. doi:10.1158/0008-5472.can-06-2473 PubMedCrossRef

Zou Y, Howell GM, Humphrey LE, Wang J, Brattain MG (2013) Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi). PLoS ONE 8:e69992. doi:10.1371/journal.pone.0069992 PubMedPubMedCentralCrossRef

Zwick E, Bange J, Ullrich A (2001) Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 8:161–173PubMedCrossRef

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2016

Rectal melanoma: epidemiology, prognosis, and role of adjuvant radiation therapy

Lower DSC1 expression is related to the poor differentiation and prognosis of head and neck squamous cell carcinoma (HNSCC)

Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients

Severe weight loss during preoperative chemoradiotherapy compromises survival outcome for patients with locally advanced rectal cancer